NanoBio And GSK Commence Phase 3 Studies Of Nanoemulsion-Based OTC Treatment For Cold Sores

(Nanowerk News) NanoBio® Corporation today announced the initiation of two Phase 3 multicenter trials evaluating NB-001 as a topical treatment for cold sores, a step forward in their OTC licensing agreement with GlaxoSmithKline Consumer Healthcare (GSK CH).
In December 2009, GSK CH licensed exclusive rights in the United States and Canada to NB-001 for the OTC treatment of cold sores. GSK currently offers the market-leading cold sore treatment Abreva, the only OTC medicine approved by the Food & Drug Administration (FDA) to shorten cold sore healing time.
The two trials of NB-001 will be conducted in 1700 subjects at 72 clinical sites and will evaluate the effectiveness of NB-001 to reduce cold sore healing time.
"Based on the efficacy of NB-001 in Phase 2, we are very optimistic about these trials and the path to FDA approval," said Mary Flack, MD, Vice President of Clinical Research, NanoBio. "Cold sores are painful and embarrassing for the roughly 20 percent of the US population that suffer from them. The initiation of these trials marks a significant step towards the commercialization of a new treatment offering for cold sores, as well as potential other new offerings to come from our nanoemulsion-based platform technology."
The trials are currently enrolling and are expected to conclude in 2012.
About NanoBio
NanoBio Corporation is a privately-held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat® technology platform. The company's lead product candidates are treatments for herpes labialis (licensed to GSK in the U.S. and Canada), onychomycosis, acne, cystic fibrosis and a broad platform of intranasal vaccines. The company's headquarters and laboratory facilities are located in Ann Arbor, Michigan.
Source: NanoBio (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: